Neuroimaging standards for research into small vessel disease-advances since 2013.
Marco Duering, Geert Jan Biessels, Amy Brodtmann...
https://pubmed.ncbi.nlm.nih.gov/37236211/Actively Recruiting
Led by Seoul National University Hospital · Updated on 2026-09-11
4016
Participants Needed
46
Research Sites
N/A
Total Duration
Researchers are evaluating the best low-density lipoprotein LDL cholesterol targets for adults who have had a small vessel occlusion SVO stroke, a subtype of ischemic stroke. This trial addresses the lack of specific guidelines for LDL cholesterol levels tailored to different types of stroke, focusing on secondary prevention to reduce the risk of future cardiovascular events in patients with SVO stroke. The study is a multicenter, prospective, randomized, open, blinded-endpoint clinical trial led by Seoul National University Hospital. Participants will be randomly assigned to one of two groups aiming for different LDL cholesterol targets an intensive group targeting LDL cholesterol below 70 mgdL and a standard group targeting LDL cholesterol between 90 and 110 mgdL. Both groups will receive lipid-lowering medications including statins andor ezetimibe, and PCSK9 inhibitors may be used if LDL targets are not reached with initial therapies. The trial plans to enroll 4,016 adults with confirmed SVO stroke within 180 days before randomization. During the study, participants will be monitored for major adverse cardiovascular events such as cardiovascular death, stroke, and acute coronary syndrome over a follow-up period of at least four years. Researchers will assess various outcomes including any stroke, ischemic stroke or transient ischemic attack, myocardial infarction, and hemorrhagic stroke. Participants will undergo regular evaluations to measure LDL cholesterol levels and cardiovascular health, with safety and adherence closely monitored throughout the trial duration.
CONDITIONS
Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke
W
Wookjin Yang, MD, PhD
S
Seung-Hoon Lee, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Seoul National University Hospital
Lead Sponsor
Hanmi Pharmaceutical co., ltd.
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 180 days before enrollment
Participants are screened for eligibility to participate in the trial.
1 visit for confirmation of stroke and eligibility
Duration - At least 4 years
Participants receive statins and/or ezetimibe, and possibly PCSK9 inhibitors, to achieve their assigned LDL cholesterol target level.
Regular visits for cholesterol monitoring and medication adjustments
Duration - At least 4 years
Participants are monitored for major adverse cardiovascular events including cardiovascular death, stroke, and acute coronary syndrome.
Periodic assessments throughout the follow-up period
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Marco Duering, Geert Jan Biessels, Amy Brodtmann...
https://pubmed.ncbi.nlm.nih.gov/37236211/Pierre Amarenco, Julien Bogousslavsky, Alfred Callahan...
https://pubmed.ncbi.nlm.nih.gov/16899775/Vincent Mok, Jong S Kim
https://pubmed.ncbi.nlm.nih.gov/26060798/H P Adams, B H Bendixen, L J Kappelle...
https://pubmed.ncbi.nlm.nih.gov/7678184/L B Goldstein, P Amarenco, M Szarek...
https://pubmed.ncbi.nlm.nih.gov/18077795/Naohisa Hosomi, Yoji Nagai, Tatsuo Kohriyama...
https://pubmed.ncbi.nlm.nih.gov/26501105/P Amarenco, J Bogousslavsky, L R Caplan...
https://pubmed.ncbi.nlm.nih.gov/23899749/Jun Yup Kim, Kyusik Kang, Jihoon Kang...
https://pubmed.ncbi.nlm.nih.gov/30558400/Pierre Amarenco, Jong S Kim, Julien Labreuche...
https://pubmed.ncbi.nlm.nih.gov/31738483/Dawn O Kleindorfer, Amytis Towfighi, Seemant Chaturvedi...
https://pubmed.ncbi.nlm.nih.gov/34024117/Seoul National University Hospital
Lead Sponsor
Hanmi Pharmaceutical co., ltd.
Collaborating Sponsor